Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2017 07:00 ET | Source: Amunix Operating Inc.

Distinguished Cancer Physician-Scientist Dr. Herbert (Bob) Pinedo joins Amunix Scientific Advisory Board

MOUNTAIN VIEW, CA--(Marketwired - March 13, 2017) - Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel biologics, announced today that Dr....
February 15, 2017 07:00 ET | Source: Amunix Operating Inc.

Amunix announces broad alliance with Genentech using XTEN(R) technology

MOUNTAIN VIEW, CA--(Marketwired - February 15, 2017) - Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel biologics, announced today that it...
February 13, 2017 07:00 ET | Source: Amunix Operating Inc.

Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer

MOUNTAIN VIEW, CA--(Marketwired - February 13, 2017) - Amunix Operating Inc., a privately held biotechnology company and developer of a broad portfolio of biopharmaceuticals based on its novel XTEN®...
January 05, 2017 12:30 ET | Source: Amunix Operating Inc.

Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology

MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement...
December 19, 2016 07:30 ET | Source: Amunix Operating Inc.

IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases

MOUNTAIN VIEW, CA--(Marketwired - December 19, 2016) - Amunix is pleased to announce that Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare...
October 17, 2016 09:00 ET | Source: Amunix Operating Inc.

Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology

MOUNTAIN VIEW, CA--(Marketwired - October 17, 2016) - Amunix is pleased to announce that Versartis Inc. (NASDAQ: VSAR) has been granted approval in Japan by the PMDA to initiate enrollment for its...
September 01, 2016 03:00 ET | Source: Amunix Operating Inc.

Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial

MOUNTAIN VIEW, CA--(Marketwired - September 01, 2016) - Amunix is pleased to announce that Versartis, Inc (NASDAQ: VSAR) has completed enrollment of a Phase 3 study of somavaratan (XTENylated...
March 03, 2016 17:04 ET | Source: Amunix Operating Inc.

Harold E. "Barry" Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors

MOUNTAIN VIEW, CA--(Marketwired - March 03, 2016) - Amunix is pleased to announce the appointment Harold E. "Barry" Selick and Walter H. Moos to the company's board of directors. "Barry and...
November 16, 2015 08:00 ET | Source: Amunix Operating Inc.

Amunix Establishes GMP Manufacturing of XTEN(TM) at UN-L BPDF

MOUNTAIN VIEW, CA--(Marketwired - Nov 16, 2015) - Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that it has completed tech transfer and...
October 26, 2015 08:00 ET | Source: Amunix Operating Inc.

Amunix Announces Extension of Evaluation Agreement With Roche

MOUNTAIN VIEW, CA--(Marketwired - Oct 26, 2015) - Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that its partner Roche has extended the...